SMI’s March Shake‑Up: High‑Growth Pharma Replaces Legacy Blue‑Chips to Drive Future Swiss Equity Momentum
SMI’s July 2026 shake‑up: Swisscom, Kühne+Nagel and Sandoz exit, Galderma and Sandoz biosimilar enter—shifting the index toward high‑growth life‑sciences and tech. Learn why investors should watch the new composition now.
3 minutes to read









